Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice

Behavioral and Brain Functions

Volumn 6, Issue , 2010, Pages

  Manzanedo, Carmen ^a   Rodríguez Arias, Marta ^a   Daza Losada, Manuel ^a   Maldonado, Concepción ^a   Aguilar, María A ^a   Miñarro, José ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABINOID; CANNABINOID 1 RECEPTOR AGONIST; DOPAMINE; RIMONABANT; SEROTONIN; BENZOXAZINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID 1 RECEPTOR; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; NEUROPROTECTIVE AGENT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; SEROTONIN RECEPTOR AFFECTING AGENT;

ANIMAL EXPERIMENT; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DEPENDENCE; DRUG USE; LOW DRUG DOSE; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RELAPSE; REWARD; ANIMAL; ANIMAL BEHAVIOR; BRAIN LEVEL; CONDITIONING; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; METABOLISM; MOUSE STRAIN; REINFORCEMENT;

ANIMALS; BEHAVIOR, ANIMAL; BENZOXAZINES; BRAIN CHEMISTRY; CALCIUM CHANNEL BLOCKERS; CONDITIONING (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXTINCTION, PSYCHOLOGICAL; MALE; MICE; MICE, INBRED STRAINS; MORPHOLINES; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NAPHTHALENES; NEUROPROTECTIVE AGENTS; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; REWARD; SEROTONIN AGENTS;

EID: 77952247343     PISSN: 17449081     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-9081-6-19     Document Type: Article

References (44)

1. Sala M, Braida D. Endocannabinoids and 3,4-methylenedioxymethamphetamine (MDMA) interaction. Pharmacol Biochem Behav 2005, 81:407-416. 10.1016/j.pbb.2005.02.016, 15927242.
2. Observatorio Español sobre drogas, Informe 2007 Plan Nacional sobre drogas. 2007, Ministerio de Sanidad y consumo, Observatorio Español sobre drogas, Informe 2007.
3. Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E. Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology 2004, 173:398-404. 10.1007/s00213-003-1719-0, 14722704.
4. Green AR, Mechan AO, Elliott JM, O'shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4 methylenedyoxymethamphetamine (MDMA, "Ecstasy"). Pharmacol Rev 2003, 55:463-508. 10.1124/pr.55.3.3, 12869661.
5. Escobedo I, O'shea E, Orio L, Sanchez V, Segura M, de la Torre R, Farre M, Green AR, Colado MI. A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after ip or striatal administration in mice. Br J Pharmacol 2005, 144:231-241. 10.1038/sj.bjp.0706071, 1575997, 15665862.
6. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988, 34:605-613.
7. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65. 10.1038/365061a0, 7689702.
8. Piomelli D. The endocannabinoid system: A drug discovery perspective. Curr Opin Investig Drugs 2005, 6:672-679.
9. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neurosci 1999, 2:358-363. 10.1038/7268, 10204543.
10. Nakazi M, Bauer U, Nickel T, Kathmann M, Schlicker E. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. N-S Arch Pharmacol 2000, 361:19-24.
11. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 2006, 29:225-232. 10.1016/j.tins.2006.01.008, 16483675.
12. Parolaro D, Rubino T. The role of endogenous cannabinoid system in drug addiction. Drug News Perspect 2008, 21:149-157.
13. Manzanedo C, Aguilar MA, Rodríguez-Arias M, Navarro M, Miñarro J. Cannabinoid agonist-induced sensitisation to morphine place preference in mice. Neuroreport 2004, 15:1373-1377.
14. Daza-Losada M, Ribeiro Do Couto B, Manzanedo C, Aguilar MA, Rodríguez-Arias M, Miñarro J. Rewarding effects and reinstatement of MDMA-induced CPP in adolescent mice. Neuropsychopharmacol 2007, 32:1750-1759.
15. Zarrindast MR, Nouri M, Ahmadi S. Cannabinoid CB1 receptors of the dorsal hippocampus are important for induction of conditioned place preference (CPP) but do not change morphine CPP. Brain Res 2007, 1163:130-137. 10.1016/j.brainres.2007.06.015, 17631872.
16. Braida D, Sala M. Role of the endocannabinoid system in MDMA intracerebral self-administration in rats. Br J Pharmacol 2002, 136:1089-1092. 10.1038/sj.bjp.0704825, 1573452, 12163340.
17. Braida D, Iosuè S, Pegorini S, Sala M. 3,4 Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system. Pharmacol Res 2005, 51:177-182. 10.1016/j.phrs.2004.07.009, 15629265.
18. Robledo P, Trigo JM, Panayi F, de la Torre R, Maldonado R. Behavioural and neurochemical effects of combined MDMA and THC administration in mice. Psychopharmacology 2007, 195:255-264. 10.1007/s00213-007-0879-8, 17684733.
19. Manzanedo C, Aguilar MA, Rodríguez-Arias M, Miñarro J. Effects of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice. Behav Brain Res 2001, 121:189-197. 10.1016/S0166-4328(01)00164-4, 11275296.
20. Braida D, Pozzi M, Cavallini R, Sala M. Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience 2001, 104:923-926. 10.1016/S0306-4522(01)00210-X, 11457579.
21. Cheer JF, Kendall DA, Marsden CA. Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology 2000, 151:25-30. 10.1007/s002130000481, 10958113.
22. Lepore M, Vorel SR, Lowinson J, Gardner EL. Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. Life Sci 1995, 56:2073-2080. 10.1016/0024-3205(95)00191-8, 7776834.
23. Valjent E, Maldonado R. A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology 2000, 147:436-438. 10.1007/s002130050013, 10672638.
24. Chaperon F, Soubrié P, Puech AJ, Thiébot MH. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 1998, 135:324-332. 10.1007/s002130050518, 9539255.
25. Rodríguez-Arias M, Manzanedo C, Roger-Sánchez C, Couto BR, Aguilar MA, Miñarro J. Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:166-171. 10.1016/j.pnpbp.2009.10.019, 19883712.
26. Gardner EL, Vorel SR. Cannabinoid transmission and reward-related events. Neurobiol Dis 1998, 5:502-533. 10.1006/nbdi.1998.0219, 9974181.
27. Hermann H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002, 109:451-480. 10.1016/S0306-4522(01)00509-7, 11823058.
28. Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM. Cannabinoid receptor-independent actions of the aminoalkylindole WIN 55,212-2 on trigeminal sensory neurons. Br J Pharmacol 2004, 142:257-266. 10.1038/sj.bjp.0705778, 1574952,1574952, 15155534.
29. Sañudo-Peña MC, Tsou K, Delay ER, Hohman AG, Force M, Walker JM. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett 1997, 223:125-128. 10.1016/S0304-3940(97)13424-3, 9089689.
30. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002, 16:1395-1398. 10.1046/j.1460-9568.2002.02192.x, 12405999.
31. Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992, 48:655-688. 10.1016/0306-4522(92)90409-U, 1376455.
32. Herkenham M, Brady LS. D9-Tetrahydrocannabinol and the synthetic cannabinoid CP-55,940 induce expression of c-Fos mRNA in stress-responsive nuclei of rat brain. Soc Neurosci Abstr 1994, 20:s1676.
33. Wu WC, Wang Y, Chai CY. Acute effects of the cannabinoid receptor agonist WIN55212-2 on dopamine release in rat: an in vivo electrochemical study. Chin J Physiol 2008, 51:152-159.
34. Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariansen JL, Aragona BJ, Phillips PE, Wightman RM. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci 2007, 27:791-795. 10.1523/JNEUROSCI.4152-06.2007, 17251418.
35. Fattore L, Spano MS, Deiana S, Melis V, Cossu G, Fadda P, Fratta W. An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives. Brain Res Rev 2007, 53:1-16. 10.1016/j.brainresrev.2006.05.003, 16839608.
36. Wiskerke J, Pattij T, Schoffelmeer AN, De Vries TJ. The role of CB1 receptors in psychostimulant addiction. Addict Biol 2008, 13:225-238. 10.1111/j.1369-1600.2008.00109.x, 18482432.
37. Beardsley PM, Thomas BF, McMahon LR. Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders. Int Rev Psychiatry 2009, 21:134-142. 10.1080/09540260902782786, 19367507.
38. Touriño C, Ledent C, Maldonado R, Valverde O. CB1 cannabinoid receptor modulates 3,4-methylenedioxymethamphetamine acute responses and reinforcement. Biol Psychiat 2008, 63:1030-1038. 10.1016/j.biopsych.2007.09.003, 17950256.
39. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 2000, 12:4038-4046. 10.1046/j.1460-9568.2000.00287.x, 11069600.
40. Pazos MR, Sagredo O, Fernández-Ruiz J. The endocannabinoid system in Huntington's disease. Curr Pharm Des 2008, 14:2317-2325. 10.2174/138161208785740108, 18781982.
41. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag 2009, 5:153-168.
42. Fisk JE, Montgomery C, Wareing M, Murphy PN. The effects of concurrent cannabis use among ecstasy users: neuroprotective or neurotoxic?. Hum Psychopharmacol 2006, 21:355-366. 10.1002/hup.777, 16915582.
43. Rubovitch V, Gafni M, Sarne Y. The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium channels in N18TG2 neuroblastoma cells. Mol Brain Res 2002, 101:93-102. 10.1016/S0169-328X(02)00174-2, 12007836.
44. Sarne Y, Keren O. Are cannabinoid drugs neurotoxic or neuroprotective?. Med Hypotheses 2004, 63:187-192. 10.1016/j.mehy.2004.02.043, 15236773.